Sử dụng Hệ thống Phân loại Tình trạng Dược phẩm (BDDCS) để Dự đoán Tình trạng Phản ứng Phụ trên Da Mang Tính Đặc hiệu Liên quan đến Việc Sử dụng Thuốc Chống Động Kinh

Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48(7):1223–44. Yang C-Y, Dao R-L, Lee T-J, Lu C-W, Yang C-H, Hung S-I, et al. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology. 2011;77(23):2025–33. Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin. 2000;18(3):181–200. Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(9):1025–32. Chung W, Hung S, Hong H, Hsih M, Yang L, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486. Hung S-I, Chung W-H, Jee S-H, Chen W-C, Chang Y-T, Lee W-R, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006;16(4):297–306. Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng ASH, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48(5):1015–8. Chang C-C, Too C-L, Murad S, Hussein SH. Association of HLA-B*1502 allele with carbamazepine- induced toxic epidermal necrolysis and Stevens–Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol. 2011;50(4):221–4. Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008;49(12):2087–91. US FDA. Information for healthcare professionals: dangerous or even fatal skin reactions - carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics). [cited 2015 Jan 5]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124718.htm. Chen P, Lin J-J, Lu C-S, Ong C-T, Hsieh PF, Yang C-C, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364(12):1126–33. Chen Z, Liew D, Kwan P. Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions. Neurology. 2014;83(22):2077–84. Handoko KB, van Puijenbroek EP, Bijl AH, Hermens WAJJ, Zwart-van Rijkom JEF, Hekster YA, et al. Influence of chemical structure on hypersensitivity reactions induced by antiepileptic drugs: the role of the aromatic ring. Drug Saf. 2008;31(8):695–702. Wang X-Q, Shi X-B, Au R, Chen F-S, Wang F, Lang S-Y. Influence of chemical structure on skin reactions induced by antiepileptic drugs—the role of the aromatic ring. Epilepsy Res. 2011;94(3):213–7. Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11–23. Hosey CM, Chan R, Benet LZ. BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs. AAPS J. 2016;18(1):251–60. Hirsch LJ, Arif H, Nahm EA, Buchsbaum R, Resor SR, Bazil CW. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology. 2008;71(19):1527–34. Wang X-Q, Lang S-Y, Shi XB, Tian HJ, Wang RF, Yang F. Antiepileptic drug-induced skin reactions: a retrospective study and analysis in 3793 Chinese patients with epilepsy. Clin Neurol Neurosurg. 2012;114(7):862–5. Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia. 2007;48(7):1360–5. Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011;13(4):519–47. Wang X-Q, Lang S, Shi X, Tian H, Wang R, Yang F. Cross-reactivity of skin rashes with current antiepileptic drugs in Chinese population. Seizure. 2010;19(9):562–6. Werhahn KJ, Klimpe S, Balkaya S, Trinka E, Krämer G. The safety and efficacy of add-on levetiracetam in elderly patients with focal epilepsy: a one-year observational study. Seizure. 2011;20(4):305–11. Cormier J, Chu CJ. Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age. Neuropsychiatr Dis Treat. 2013;9:295–306. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome in children: incidence, prevention and management. CNS Drugs. 2002;16(2):197–205. Naisbitt DJ, Farrell J, Wong G, Depta JPH, Dodd CC, Hopkins JE, et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol. 2003;111(6):1393–403. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JPH, Chadwick DW, et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol. 2003;63(3):732–41. Arif H, Buchsbaum R, Weintraub D, Koyfman S, Salas-Humara C, Bazil CW, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology. 2007;68(20):1701–9. Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol. 2009;28(1):1–10. US FDA. Information for Healthcare Professionals: Phenytoin (marketed as Dilantin, Phenytek and generics) and Fosphenytoin Sodium (marketed as Cerebyx and generics). [cited 2015 Jan 5]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124788.htm. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavičiūtė D, Carrington M, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134–43. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 2010;51(12):2461–5. U.S. National Library of Medicine. DailyMed. [cited 2015 Nov 1]. Available from: http://dailymed.nlm.nih.gov/dailymed/. Sperling M, Asadi-Pooya A. Antiepileptic drugs: a clinician’s manual. New York: Oxford University Press; 2009. p. 201–9. Ahmad AM. In vitro-in vivo correlation of modified release dosage form of lamotrigine. Biopharm Drug Dispos. 2009;30(9):524–31. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64(7):1134–8. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook. 17th ed. Hudson: Lexi-Comp, Inc.; 2008. Bialer M, Midha KK. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. Epilepsia. 2010;51(6):941–50. US FDA. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System guidance for industry. Rockville, MD 20852; 2015. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070246.pdf. Anderson GD. Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. Ther Drug Monit. 2008;30(2):173–80. Shorvon SD. Handbook of epilepsy treatment. 3rd ed. Oxford: Wiley-Blackwell; 2010. p. 376. Broccatelli F, Mannhold R, Moriconi A, Giuli S, Carosati E. QSAR modeling and data mining link Torsades de Pointes risk to the interplay of extent of metabolism, active transport, and hERG liability. Mol Pharm. 2012;9(8):2290–301. Vuppalanchi R, Gotur R, Reddy KR, Fontana RJ, Ghabril M, Kosinski AS, et al. Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome. Clin Gastroenterol Hepatol. 2014;12(9):1550–5. Haidu P, Uihlein M, Damm D. Quantitative determination of clobazam in serum and urine by gas chromatography, thin layer chromatography and fluorometry. J Clin Chem Clin Biochem. 1980;18(4):209–14. Anderson G. Understanding the ramifications of switching among AEDs: what are the data? Adv Stud Pharm. 2008;5(5):146–51.